FDA Accepts Investigational New Drug Application For ARI-2243 And A First In Man Clinical Trial Set To Begin During ... (Medical News Today)
Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted the company's recently submitted Investigational New Drug (IND) application to evaluate ARI-2243 in a phase I clinical trial in healthy volunteers.

Strides Arcolab Bags Two ANDA Approvals (Nasdaq)
(RTTNews) - Wednesday, Strides Arcolab said that the company bagged two ANDA approvals. The first one is from Health Canada for Tazo Pip Sterile injection in three presentations. The product is licensed to an undisclosed partner in Canada and the company expects to launch the product immediately.

Akorn-Strides, LLC Announces FDA Approval For Tobramycin Injection USP, 80 Mg/2mL And 1.2 Grams/30mL (Medical News Today)
Akorn-Strides, LLC announced the approval of an ANDA for Tobramycin Injection USP, 80 mg/2mL and 1.2 grams/30mL. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE: STAR, BSE: 532531).